Cargando…
Cancer Stem Cells: Powerful Targets to Improve Current Anticancer Therapeutics
A frequent observation in several malignancies is the development of resistance to therapy that results in frequent tumor relapse and metastasis. Much of the tumor resistance phenotype comes from its heterogeneity that halts the ability of therapeutic agents to eliminate all cancer cells effectively...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874936/ https://www.ncbi.nlm.nih.gov/pubmed/31781251 http://dx.doi.org/10.1155/2019/9618065 |
_version_ | 1783472917955215360 |
---|---|
author | Bighetti-Trevisan, Rayana L. Sousa, Lucas O. Castilho, Rogerio M. Almeida, Luciana O. |
author_facet | Bighetti-Trevisan, Rayana L. Sousa, Lucas O. Castilho, Rogerio M. Almeida, Luciana O. |
author_sort | Bighetti-Trevisan, Rayana L. |
collection | PubMed |
description | A frequent observation in several malignancies is the development of resistance to therapy that results in frequent tumor relapse and metastasis. Much of the tumor resistance phenotype comes from its heterogeneity that halts the ability of therapeutic agents to eliminate all cancer cells effectively. Tumor heterogeneity is, in part, controlled by cancer stem cells (CSC). CSC may be considered the reservoir of cancer cells as they exhibit properties of self-renewal and plasticity and the capability of reestablishing a heterogeneous tumor cell population. The endowed resistance mechanisms of CSC are mainly attributed to several factors including cellular quiescence, accumulation of ABC transporters, disruption of apoptosis, epigenetic reprogramming, and metabolism. There is a current need to develop new therapeutic drugs capable of targeting CSC to overcome tumor resistance. Emerging in vitro and in vivo studies strongly support the potential benefits of combination therapies capable of targeting cancer stem cell-targeting agents. Clinical trials are still underway to address the pharmacokinetics, safety, and efficacy of combination treatment. This review will address the main characteristics, therapeutic implications, and perspectives of targeting CSC to improve current anticancer therapeutics. |
format | Online Article Text |
id | pubmed-6874936 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-68749362019-11-28 Cancer Stem Cells: Powerful Targets to Improve Current Anticancer Therapeutics Bighetti-Trevisan, Rayana L. Sousa, Lucas O. Castilho, Rogerio M. Almeida, Luciana O. Stem Cells Int Review Article A frequent observation in several malignancies is the development of resistance to therapy that results in frequent tumor relapse and metastasis. Much of the tumor resistance phenotype comes from its heterogeneity that halts the ability of therapeutic agents to eliminate all cancer cells effectively. Tumor heterogeneity is, in part, controlled by cancer stem cells (CSC). CSC may be considered the reservoir of cancer cells as they exhibit properties of self-renewal and plasticity and the capability of reestablishing a heterogeneous tumor cell population. The endowed resistance mechanisms of CSC are mainly attributed to several factors including cellular quiescence, accumulation of ABC transporters, disruption of apoptosis, epigenetic reprogramming, and metabolism. There is a current need to develop new therapeutic drugs capable of targeting CSC to overcome tumor resistance. Emerging in vitro and in vivo studies strongly support the potential benefits of combination therapies capable of targeting cancer stem cell-targeting agents. Clinical trials are still underway to address the pharmacokinetics, safety, and efficacy of combination treatment. This review will address the main characteristics, therapeutic implications, and perspectives of targeting CSC to improve current anticancer therapeutics. Hindawi 2019-11-12 /pmc/articles/PMC6874936/ /pubmed/31781251 http://dx.doi.org/10.1155/2019/9618065 Text en Copyright © 2019 Rayana L. Bighetti-Trevisan et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Bighetti-Trevisan, Rayana L. Sousa, Lucas O. Castilho, Rogerio M. Almeida, Luciana O. Cancer Stem Cells: Powerful Targets to Improve Current Anticancer Therapeutics |
title | Cancer Stem Cells: Powerful Targets to Improve Current Anticancer Therapeutics |
title_full | Cancer Stem Cells: Powerful Targets to Improve Current Anticancer Therapeutics |
title_fullStr | Cancer Stem Cells: Powerful Targets to Improve Current Anticancer Therapeutics |
title_full_unstemmed | Cancer Stem Cells: Powerful Targets to Improve Current Anticancer Therapeutics |
title_short | Cancer Stem Cells: Powerful Targets to Improve Current Anticancer Therapeutics |
title_sort | cancer stem cells: powerful targets to improve current anticancer therapeutics |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874936/ https://www.ncbi.nlm.nih.gov/pubmed/31781251 http://dx.doi.org/10.1155/2019/9618065 |
work_keys_str_mv | AT bighettitrevisanrayanal cancerstemcellspowerfultargetstoimprovecurrentanticancertherapeutics AT sousalucaso cancerstemcellspowerfultargetstoimprovecurrentanticancertherapeutics AT castilhorogeriom cancerstemcellspowerfultargetstoimprovecurrentanticancertherapeutics AT almeidalucianao cancerstemcellspowerfultargetstoimprovecurrentanticancertherapeutics |